Company intelligence / Profile preview

NanoRepro

Ownership: Private
Development stage: Commercial

Overview

NanoRepro AG has a commercial portfolio of at least 24 CE-marked rapid diagnostic self-tests and food supplements for home and professional use. The company focuses on accuracy in self-diagnostics for rapid disease detection across family planning, preventive healthcare, allergies, infectious diseases, and food intolerances. No clinical trial results are reported as the products are diagnostics rather than therapeutics.

Therapeutic areas: Women's HealthImmunologyOtherGastroenterologyInfectious Diseases
Modalities: Device
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on NanoRepro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoRepro.

Explore the full profile